+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cancer Immunotherapy"

Immunotherapy Drugs - Global Strategic Business Report - Product Thumbnail Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 193 Pages
  • Global
From
Cancer Therapies - Global Strategic Business Report - Product Thumbnail Image

Cancer Therapies - Global Strategic Business Report

  • Report
  • August 2025
  • 590 Pages
  • Global
From
T-Cell Malignancies - Pipeline Insight, 2025 - Product Thumbnail Image

T-Cell Malignancies - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 280 Pages
  • Global
From
From
Malignant Pleural Mesothelioma- Pipeline Insight, 2025 - Product Thumbnail Image

Malignant Pleural Mesothelioma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
NK Cell Therapies - Pipeline Insight, 2025 - Product Thumbnail Image

NK Cell Therapies - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025 - Product Thumbnail Image

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Head And Neck Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Head And Neck Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
Ewing Sarcoma - Pipeline Insight, 2025 - Product Thumbnail Image

Ewing Sarcoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 115 Pages
  • Global
From
PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025 - Product Thumbnail Image

PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025

  • Report
  • April 2025
  • 400 Pages
  • Global
From
Anti-CD40 Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD40 Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
IPSC Derived NK Cells- Pipeline Insight, 2025 - Product Thumbnail Image

IPSC Derived NK Cells- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Immunotherapy Drugs Market 2025-2033 - Product Thumbnail Image

Immunotherapy Drugs Market 2025-2033

  • Report
  • March 2025
  • 149 Pages
  • Global
From
From
From
From
From
Loading Indicator

Cancer Immunotherapy is a type of Immune Disorders Drugs that uses the body's own immune system to fight cancer. It works by stimulating the body's natural defense system to recognize and attack cancer cells. This type of therapy is used to treat a variety of cancers, including melanoma, lymphoma, and leukemia. It can also be used to treat other types of cancer, such as breast, lung, and colorectal cancer. Cancer Immunotherapy is a rapidly growing field, with many new treatments being developed. It is an important part of the overall cancer treatment landscape, as it can provide a more targeted approach to treating cancer. It can also be used in combination with other treatments, such as chemotherapy and radiation therapy, to improve outcomes. Some of the companies in the Cancer Immunotherapy market include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Roche. These companies are developing a range of treatments, including monoclonal antibodies, vaccines, and cell-based therapies. Show Less Read more